Stockhub

THELMA Therapeutics Co., Ltd.

Revision as of 09:48, 22 September 2022 by 95.149.241.133 (talk) (Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == THELMA Therapeutics Co., Ltd. operates as a biopharmaceutical company in South Korea and internationally. The company develops TLM-01, a non-alcoholic steatohepatitis drug; TLM-02, an antiviral agent for COVID-19; TLM-03/TLM-04, an anticancer drug for solid and blood cancer; and TLM-05, a liver cancer drug. It also offers radioembolization and brachytherapy devices for the cancer treatments. The company was formerly known a...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Summary[1] edit edit source

THELMA Therapeutics Co., Ltd. operates as a biopharmaceutical company in South Korea and internationally. The company develops TLM-01, a non-alcoholic steatohepatitis drug; TLM-02, an antiviral agent for COVID-19; TLM-03/TLM-04, an anticancer drug for solid and blood cancer; and TLM-05, a liver cancer drug. It also offers radioembolization and brachytherapy devices for the cancer treatments. The company was formerly known as Medipartner Biotechnology. Co., Ltd. THELMA Therapeutics Co., Ltd. was founded in 1981 and is headquartered in Seoul, South Korea.

References and notes edit edit source

  1. ↑ Source: Yahoo Finance.
Retrieved from "https://stockhub.co/index.php?title=THELMA_Therapeutics_Co.,_Ltd.&oldid=67990"